Skip to Content

'
Luis E. Fayad

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX
Clinical Medical Director, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Staff Physician, Lyndon B. Johnson Hospital, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd Unit 429
Unit Number: 429
Houston, TX 77030
Room Number: FC6.2018
Phone: 713-792-2860
Fax: 713-794-5656
Email: lefayad@mdanderson.org

Education & Training

Degree-Granting Education

1985 Catholic University of Guayaquil, Guayaquil, Ecuador, MD, Medicine

Postgraduate Training

7/1994-6/1997 Medical Oncology Fellowship, Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1993-6/1994 Hematology Fellowship, Hematology, University of Texas Health Science Center, Houston, TX
7/1990-6/1993 Internal Medicine Program, Internal Medicine, University of Miami/Jackson Memorial Hospital, Miami, FL

Board Certifications

10/2012 American Board of Internal Medicine
10/2012 American Board of Internal Medicine Medical Oncolo
1/1998 American Board of Internal Medicine Hematology sub

Experience/Service

Academic Appointments

Assistant Professor, University of Texas M.D. Anderson Cancer Center, Houston, TX, 1/2000-9/2006
Assistant Professor, University of Nevada School of Medicine, Las Vegas, NV, 1/1998-1/2000
Hematology Oncologist, Nevada Cancer Center, Las Vegas, NV, 1/1997-1/2000

Other Appointments/Responsibilities

Staff Physician, Lyndon B. Johnson Hospital, Houston, TX, 9/2002-2010

Institutional Committee Activities

Member, Provider Ambassador Network Focus Group, 2010-present
Director, Lymphoma Planning Clinic, 2010-present
Member, CME Advisory Committee, 2008-present
Alternative Member, Medical Records Committee, 2005-present
Medical Liaison, Pharmacy Assistant Program, 2005-2011
Member, CRC (Clinical Research Committee), 9/2003-8/2006
Member, CCAG (Clinical Computing Advisory Group) Committee, 1/2002-2007
Member, Pharmacy and Therapeutics Committee, 1/2001-2005
Member, IRB, 1/1999-2011
Member, Institutional Review Board for Columbia Sunrise Hospital, 1/1999-1/2000
Member, European Society of Medical Oncology, 1/1998-present
Member, Nevada State Medical Association, 1/1998-present
Member, CCOP, 1/1998-2004
Member, Q & A of CCOP, 1/1998-2004
Member, American Society of Hematology, 1/1997-present
Member, American Society of Oncology, 1/1997-present
Member, American Society of Internal Medicine, 1997-present
Member, American Society of Bone Marrow Transplantation, 1997-present
Member, Texas Medical Association, 1/1996-present
Member, American College of Physicians, 1/1994-present

Honors and Awards

2009-present Best Doctors of America
2005 Mentor Award 2005, M. D. Anderson Alumni and Faculty Association

Professional Memberships

NCCN Hon Hodgkin's Lymphoma Panel
Member, 2005-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Fayad LE, Romaguera JE, Wang M, Kwak L. Bortezomib-resistant nuclear factor kappa B expression in stem like cells in mantle cells lymphoma (MCL). Exp Hematol. In Press.
2. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double Hit Lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 9/2014. e-Pub 6/2014. PMID: 24943107.
3. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 4.2014. J Natl Compr Canc Netw 12(9):1282-303, 9/2014. PMID: 25190696.
4. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 2.2014. J Natl Compr Canc Netw 12(6):916-46, 6/2014. PMID: 24925202.
5. Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. Int J Radiat Oncol Biol Phys 89(2):384-91, 6/2014. e-Pub 4/2014. PMID: 24721592.
6. Westin J, Oki Y, Fayad L. Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al. Br J Haematol 165(1):146-7, 4/2014. e-Pub 12/16/2013. PMID: 24329994.
7. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/6/2014. PMID: 24386943.
8. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM. Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins. J Clin Oncol 32(8):798-808, 3/10/2014. e-Pub 12/16/2013. PMCID: PMC3940538.
9. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. J Clin Oncol 32(2):114-20, 1/2014. e-Pub 12/2013. PMID: 24323027.
10. Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J, Kwak LW, Pro B, de Castro Faria S, Neelapu S, Fowler N, Hagemeister F, Zhang J, Zhou S, Feng L, Younes A. Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. Clin Cancer Res 19(24):6882-90, 12/15/2013. e-Pub 10/4/2013. PMID: 24097867.
11. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW, Podoloff D, Oki Y, Hagemeister FB, Chuang H, Fayad LE, Westin JR, Shihadeh F, Allen PK, Wogan CF, Rodriguez MA. Clinical Implications of PET-Negative Residual CT Masses after Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma 54(12):2631-8, 12/2013. e-Pub 5/7/2013. PMCID: PMC3827734.
12. Oki Y, Westin JR, Vega F, Chuang H, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol 163(5):611-20, 12/2013. e-Pub 10/1/2013. PMID: 24117234.
13. Romaguera JE, Fayad LE, Wang M, McLaughlin PW, Neelapu S. Nuclear Translocation of B-cell specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma. PLOS one, 9/2013. PMID: 23936317.
14. Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S. Recent advances in de novo CD5(+) Diffuse Large B cell Lymphoma (DLBCL). Am J Hematol 88(9):798-802, 9/2013. e-Pub 6/2013. PMID: 23695956.
15. Loo EY, Medeiros LJ, Aladily TN, Hoehn D, Kanagal-Shamanna R, Young KH, Lin P, Bueso-Ramos CE, Manning JT, Patel K, Thomazy V, Brynes RK, Goswami M, Fayad LE, Miranda RN. Classical hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicophathologic study of 10 cases. Am J Surg Pathol 37(8):1290-7, 8/2013. e-Pub 6/2013. PMID: 23774171.
16. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 162(1):138-41, 7/2013. e-Pub 4/17/2013. PMID: 23590726.
17. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad LE, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera JE, Samaneigo F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (marqibo) substituted for non-liposomal vincristine in CHOP with or without rituximab for patients with untreated aggressive non-hodgkin's lymphomas. Br J Haemaol, 6/2013. e-Pub 6/2013. PMID: 238027358.
18. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, Van Rhee F. A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease. Clin Cancer Res. e-Pub 5/2013. PMID: 23659971.
19. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Henkel K, Liao Q, Edvardsen K, Jewell RC, Fecteau D, Singh RP, Lisby S, Moskowitz CH. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. e-Pub 5/2013. PMID: 23692856.
20. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, McLaughlin P, Oki Y, Pro B, Rodriguez MA, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry K, Desai M, Badillo M, Bejarano M, Sun L, Young KH, Samuel C, Hartig K, Chen W, Byrne C, Bell N, Takashida K, Champlin R, Kwak L, Fayad L. Lenalidomide in combination with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma, follicular grade 3 lymphoma, and transformed B cell lymphoma: a phase 2 clinical trial. Leukemia, 4/2013. e-Pub 4/2013. PMID: 23545991.
21. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera JE, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad LE. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia, 4/2013. e-Pub 4/2013. PMID: 23545991.
22. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. e-Pub 12/29/2012. PMID: 23276888.
23. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's Lymphomas, Version 1.2013. J Natl Compr Canc Netw 11(3):257-273, 3/2013. PMID: 23486452.
24. Fayad LE, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH. Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. J Clin Oncol. e-Pub 1/2013. PMID: 23295790.
25. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk. e-Pub 11/2012. PMID: 23137719.
26. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, McCarty N. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol 159(2):243-6, 10/2012. e-Pub 8/2012. PMCID: PMC3460105.
27. Aladily TN, Medeiros LJ, Amin MB, Haideri N, Ye D, Azevedo SJ, Jorgensen JL, de Peralta-Venturina M, Mustafa EB, Young KH, You MJ, Fayad LE, Blenc AM, Miranda RN. Anaplastic Large Cell Lymphoma Associated With Breast Implants: A Report of 13 Cases. Am J Surg Pathol 36(7):1000-1008, 7/2012. PMID: 22613996.
28. Wang M, Fayad LE, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak LW, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera JE. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncology 13(7):716-723, 6/2012.
29. Oki Y, Copeland A, Romaguera J, Fayad L, Fanale M, Faria Sde C, Medeiros LJ, Ivy P, Younes A. Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma. Leuk Lymphoma 53(5):990-2, 5/2012. e-Pub 3/13/2012. PMID: 21988665.
30. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 5/2012. e-Pub 2/2012. PMCID: PMC3359733.
31. Weng J, Rawal S, Park HJ, Sharma R, Fayad LE, Fanale M, Romaguera JE, Luong A, Kwak LW, Neelapu SS. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood, 5/2012.
32. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 4/2012. e-Pub 2/21/2012. PMID: 22357140.
33. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Dirienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A, on behalf of the 405 Study Investigators. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 119(16):3698-3704, 4/2012. e-Pub 3/2012. PMID: 22389254.
34. Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 118(6):1566-73, 3/15/2012. e-Pub 8/31/2011. PMID: 21882178.
35. Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma (MCL) via manipulation of tissue transglutaminase activities. Blood 119(11):2568-78, 3/2012. e-Pub 1/2012. PMID: 22294726.
36. Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, Younes A. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood 119(9):2171-2, 3/2012. PMID: 22383790.
37. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, Kwak LW, McCarty N. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 40(2):107-18.e2, 2/2012. e-Pub 10/21/2011. PMID: 22024108.
38. Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 25(1):145-56, 1/2012. e-Pub 10/14/2011. PMID: 22002575.
39. Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. Leuk Lymphoma 53(1):50-6, 1/2012. e-Pub 10/24/2011. PMID: 21895545.
40. Srokowski TP, Liebmann JE, Modiano MR, Cohen GI, Pro B, Romaguera JE, Kuepfer C, Singer JW, Fayad LE. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Phase 1 Study With a Dose-Expansion Cohort. Cancer 117(22):5067-73, 11/15/2011. e-Pub 6/16/2011. PMID: 21681734.
41. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez MA, Hagemeister FB, Buesco-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah JJ, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann of Oncol 10:1093, 10/2011.
42. Jones RJ, Baladandayuthapani V, Neelapu S, Fayad LE, Romaguera JE, Wang M, Sharma R, Yang D, Orlowski RZ. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma. Blood 118(15):4140-9, 10/2011. e-Pub 8/2011. PMID: 21844567.
43. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 7/2011. e-Pub 4/2011. PMID: 21517809.
44. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw 9(5):484-560, 5/2011. PMID: 21550968.
45. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep 6(1):58-66, 3/2011. PMID: 21191675.
46. Greaves WO, Bueso-Ramos C, Fayad L. Classical Hodgkin's Lymphoma Associated With Langerhans Cell Histiocytosis: Multiagent Chemotherapy Resulted in Histologic Resolution of Both the Classical Hodgkin's Lymphoma and Langerhans Cell Proliferation Components. J Clin Oncol 29(4):e76-8, 2/2011. e-Pub 11/2010. PMID: 21041711.
47. Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, Caraway N, Neelapu SS, Kwak LW, Simmons PJ, McCarty N. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res 5(3):212-25, 11/2010. e-Pub 8/6/2010. PMCID: PMC2952723.
48. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 123(10):935-41, 10/2010. PMID: 20920696.
49. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez A, Wang M, Weaver P, Hartig K, Kwak LW, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151(1):47-53, 10/2010. e-Pub 8/2010. PMID: 20735402.
50. Phan J, Mazloom A, Medeiros LJ, Zreik TG, Wogan C, Shihadeh F, Rodriguez MA, Fayad L, Fowler N, Reed V, Horace P, Dabaja BS. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 28(27):4170-6, 9/2010. e-Pub 8/2010. PMID: 20713859.
51. Jones JA, Fayad LE, Elting LS, Rodriguez MA. Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 51(9):1649-57, 9/2010. PMID: 20807093.
52. Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, Pro B, Gonzalez G, Iyengar P, Urbauer DL, Dabaja BS. Marginal zone lymphomas: factors that affect the final outcome. Cancer 116(18):4291-8, 9/2010. e-Pub 6/2010. PMID: 20549822.
53. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a Novel Anti-Interleukin-6 Monoclonal Antibody, for Castleman's Disease. J Clin Oncol 28(23):3701-8, 8/2010. e-Pub 7/2010. PMID: 20625121.
54. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 7/2010. e-Pub 5/2010. PMID: 20528872.
55. Juweid ME, Thomas D, Menda Y, Tewson T, Graham MM, Herrmann K, Buck AK, Fayad L. PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity. J Nucl Med 51(5):824-5, 5/2010. PMID: 20439512.
56. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 28(12):2085-93, 4/2010. e-Pub 3/2010. PMID: 20308665.
57. Tomas JF, Dang J, Pro B, Rodriguez MA, McLaughlin P, Romaguera JE, Younes A, Hagemeister F, Cabanillas F, Podoloff D, Fayad LE. El tamizaje con galio despues del segundo y cuarto ciclos de quimioterapia es predictor de linfomas no Hodgkin. Revista de Hematol 11:5-14, 3/2010.
58. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 8(3):288-334, 3/2010. PMID: 20202462.
59. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms. J Clin Oncol 27(32):5425-30, 11/2009. e-Pub 10/2009. PMID: 19805674.
60. Westin JR, Fayad LE. Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep 4(4):218-24, 10/2009. PMID: 20425411.
61. Kim JE, Singh RR, Cho-Vega JH, Drakos E, Davuluri Y, Khokhar FA, Fayad L, Medeiros LJ, Vega F. Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-Cell lymphoma. Mod Pathol 22(10):1312-20, 10/2009. e-Pub 7/2009. PMID: 19593328.
62. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: Phase I/II results. J Clin Oncol 27(20):3346-53, 7/2009. e-Pub 5/2009. PMID: 19451441.
63. Esmaeli B, McLaughlin P, Pro B, Samaniego F, Gayed I, Hagemeister F, Romaguera J, Cabanillas F, Neelapu SS, Banay R, Fayad L, Wayne Saville M, Kwak LW. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol 20(4):709-14, 4/2009. e-Pub 1/2009. PMID: 19150940.
64. Wang M, Fayad L, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez MA, Kwak LW, Zhou Y, Kantarjian H, Romaguera J. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113(10):2734-41, 11/2008. PMID: 18973182.
65. Shah JJ, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 112(6):2583; author reply 2583-4, 9/2008. PMID: 18779406.
66. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 143(3). e-Pub 9/2008. PMID: 18764869.
67. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12). e-Pub 4/2008. PMID: 18411419.
68. Zelenter AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacase AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 6(4):356-421, 4/2008. PMID: 18433606.
69. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol 112(4):553-559, 3/2008. e-Pub 12/2007. PMID: 18083690.
70. Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Veno NT; Hosing C; Khouri IF; Couril D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience. Haematologica 93(2):257-264, 2/2008. e-Pub 1/2008. PMID: 18223284.
71. Oki Y; Pro B; Fayad LE; Romaguera J; Samaniego F; Hagemeister F; Neelapu S; McLaughlin P; Goy A; Younes A. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 112(4):831-836, 2/2008. PMID: 18085611.
72. Provencio M, Fayad LE. [High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma]. Med Clin (Barc) 130(2):60-5, 1/2008. PMID: 18221676.
73. Friedberg JW, Williams ME, van der Jagt RH, Forero-Torres A, LaCasce AS, Fayad LE, Bessudo A, Camacho ES, Oliver JW, Chen L, Cohen P, Cheson BD, Robinson KS. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204-210, 1/2008. PMID: 18182663.
74. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2:S57-62, 12/2007. PMID: 18284717.
75. Soriano AO, Thompson MA, Admirand JH, Fayad LE, Rodriguez AM, Romaguera JE, Hagemeister FB, Pro B.. Follicular dendritic cell sarcoma: A report of 14 cases and a review of the literature. Am J Hematol 82(8)(8):725-8, 8/2007. PMID: 17373675.
76. Dang NH, Fayad L, McLaughlin P, Romaguara JE, Hagemeister F, Goy A, Neelapu S, Samaniego F, Walker PL, Wang M, Rodriguez MA, Tong AT, Pro B.. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol 138(4)(4):502-505, 8/2007. e-Pub 6/29/2007. PMID: 17608763.
77. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109(12):2481-9, 6/15/2007. PMID: 17497648.
78. Iwuanyanwu E, Medeiros J, Romaguera JE, Fayad L.. Mantle Cell Lymphoma with a Rare Involvement of the Testicle. Leuk Lymphoma 48(6)(6):1242-3, 6/2007. PMID: 17577795.
79. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L. Pre-transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma. Cancer 109(12):2481-9, 6/2007.
80. Fayad L, Hagemeister F. Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed. Leuk Lymphoma 48(4):657-8, 4/2007. PMID: 17454622.
81. Wang S, Wang S, Maeng H, Young DP, Prakash O, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109(5):2174-82, 3/2007. e-Pub 11/7/2006. PMCID: PMC1801039.
82. Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 48(2):374-80, 2/2007. PMID: 17325899.
83. Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 136(3):439-47, 2/2007. PMID: 17233846.
84. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastaba PK, Younes A. Experience with heat schock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109(1):77-83, 1/2007.
85. Hagemeister FB, Fayad L. The FLIPI and the R-FLIPI: Are we finally ready to use them in Clinical Trials? Am J Hem-Onc 6(6):364-368, 2007.
86. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad,, II, Couch RB. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis 194(10):1394-7, 11/2006. e-Pub 10/6/2006. PMID: 17054068.
87. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer 42(17):2976-81, 11/2006. e-Pub 9/27/2006. PMID: 17008093.
88. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-302, 9/2006. PMID: 16902984.
89. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24(10):1582-9, 4/2006. PMID: 16575009.
90. Fayad L, Younes A. Novel treatment strategies for aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 7(6):733-48, 4/2006. PMID: 16556089.
91. Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(3):258-310, 3/2006. PMID: 16507273.
92. Pro B, Fayad L, McLaughlin P, Romaguera J, Hagemeister FB, Rodriguez MA, Goy A, Loyer E, Younes A. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 47(3):481-5, 3/2006. PMID: 16396772.
93. Younes A, Pro B, Fayad L. Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107(4):1731-2, 2/2006. PMID: 16461762.
94. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013-23, 10/2005. e-Pub 9/6/2005. PMID: 16145068.
95. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin RE. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35(10):943-51, 5/2005. PMID: 15806128.
96. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-7, 4/2005. PMID: 15800314.
97. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23(4):667-75, 2/2005. e-Pub 12/21/2004. PMID: 15613697.
98. Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol 22(20):4095-102, 10/2004. e-Pub 9/7/2004. PMID: 15353540.
99. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin RE. Non-ablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 21(23):4407-12, 12/2003. PMID: 14645431.
100. Ha CS, Kong JS, McLaughlin P, Tucker SL, Fayad LE, Hess MA, Wilder RB, Cabanillas F, Cox JD. Stage III follicular lymphoma: long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 57(3):748-54, 11/2003. PMID: 14529780.
101. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10(5):1513-8, Sep-Oct, 9/2003. PMID: 12883733.
102. Goy A, Ramdas L, Remache YK, Gu J, Fayad L, Hayes KJ, Coombes KR, Barkoh BA, Katz R, Ford R, Cabanillas F, Gilles F. Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations. Lab Invest 83(6):913-6, 6/2003. PMID: 12808126.
103. Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IF. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 14(5):737-44, 5/2003. PMID: 12702528.
104. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, Younes A, McLaughlin P, Goy A, Sarris AH, Dang NH, Samaniego F, Brown HM, Gagneja HK, Cabanillas F. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97(3):586-91, 2/2003. PMID: 12548600.
105. Fayad L. Durable Local responses with Subtherapeutic doses of concurrent Radiation and Gemcitabine in a patient with refractory Hodgkin’s disease: Review of Halepota et al case. Clin Adv in Hematol & Oncol. 1(7):416, 2003.
106. Fayad L, Pro B, Romaguera JE. Mantle cell lymphoma: A review. Hematología, Citocinas, Y Terapia Celular 2:100-112, 2003.
107. Younes A, Fayad L, Pro B, McLaughlin P, Hagemeister F, Mansfield P, Clayman G, Medeiros LJ, Manning J, Lewis J, Srivastava P. Safety and Efficacy of Heat Shock Protein-Peptide 96 Complex (HSPPC-96) Vaccine Therapy in Patients with Relapsed or Previously Untreated Low-Grade Non-Hodgkin Lymphoma. Blood 102(11):898a, 2003.
108. Fayad L, Keating MJ, Reuben JM, O'Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 97(1):256-63, 2001. PMID: 11133769.

Editorials

1. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/11/2013. PMID: 24332512.
Other Articles
1. Provencio M; Fayad LE. High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma. Medicina clinica 130(2):60-65, 1/2008.

Abstracts

1. Fanale MA, Samaniego F, Fayad LE, Hagemeister FB, McLaughlin P, Rodriguez MA, Weaver P, Hartig K, Badillo M, Kwak LW, Younes A, Pro B, Wang M. Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 122(21):5122, 12/2013.
2. Garrido-Laguna I, Velez-Bravo V, Falchook GS, Subbiah V, Hong DS, Oki Y, Westin JR, Nunez CA, Fayad LE, Kwak LW, Shpall EJ, Wheler JJ, Liang W, Salhia B, Meric-Bernstam F, Kurzrock R, Fanale MA. Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. Blood (ASH Annual Meeting Abstracts) 122(21):3048, 12/2013.
3. Hong DS, Younes A, Fayad LE, Fowler NH, Hagemeister FB, Mistry R, Nemunaitis JJ, Borad MJ, Bryce AH, Yamashita M, Hughes SG, KwohTJ, MacLeod AR, Norris D, Baldwin R, Hung G, Monia BP, Kurzrock R. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. J Clin Oncol, 6/2013.
4. Pham LV, Rollo A, Tamayo AT, Lee J, Zuo Z, Sun L, Zhang L, Ou Z, Fayad LE, Wang M, Ford RJ. Biological Significance of the Immumoproteasome Subunits Mecl-1 and LMP-2 in Diffuse Large B-Cell Lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(120):2717, 11/2012.
5. Khouri IF, Rima SM, Turturro F, Korbling M, Ledesma C, Rondon G, Alousi AM, Anderlini P, Bash Q, Ciurea SO, Hosing CM, Popat UR, Charafeddine Y, Oki Y, Fayad LE, Champlin RE. Bortezomib and BEAM-Rituximab Reduced-Intensity Conditioning for High-Risk Lymphoma Patients Who Are Not Eligible for Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood Blood (ASH Annual Meeting Abstracts)(120):4157, 11/2012.
6. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte L, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood Blood (ASH Annual Meeting Abstracts)(120):901, 11/2012.
7. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(120):793, 11/2012.
8. Fanale MA, Lai CM, Rimes SA, Ramirez MM, Hagemeister FB, Fowler NH, Younes A, Fayad LE, Rodriguez MA, Turturro F, Samaniego F, Romaguera JE, Levin VA, Horowitz SB, Woolery JE, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. Blood Blood (ASH Annual Meeting Abstracts)(120):3670, 11/2012.
9. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad LE. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood Blood (ASH Annual Meeting Abstracts)(120):3707, 11/2012.
10. Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad LE, Wang M, McLaughlin P, McDonnell TJ, Patel KP, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood Blood (ASH Annual Meeting Abstracts)(120):2406, 11/2012.
11. Zhang K, Pham LV, Tamayo AT, Lee J, Bryant J, Younes A, Fayad LE, Yang DJ, Ford RJ. Reversing Metabolic and Epigenetic Cellular Alterations to Overcome Chemo-Resistance in Aggressive B Cell Lymphomas. Blood Blood (ASH Annual Meeting Abstracts)(120):1305, 11/2012.
12. Takahashi K, Sivina M, Oki Y, Fayad LE, Neelapu SS, Kwak LW, Xiao L, Huang X, Fu K, Chung Chan W, Vose J, Kantarjian HM, Keating M, Burger JA. Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(120):2709, 11/2012.
13. Oki Y, Chuang H, Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad LE, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(120):1529, 11/2012.
14. Batty N, Ghonimi E, Feng L, Fayad LE, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. Comparison of the international prognostic factors index (IPI) with the absolute monocyte and lymphocyte prognostic index (AMLPI) for patients (Pts) with diffuse large b-cell lymphoma (DLBCL) receiving R-CHOP. J Clin Oncol J Clin Oncol 30(30):8067, 6/2012.
15. Jabbour E, O'Brien SM, Thomas D, Jorgensen JL, Kebriaei P, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad LE, Tarnai R, Wang S, Champlin RE, Advani AS, Kantarjian H. Inotuzumab ozogamycin (I0), a CD22 monoclonal antibody conjugated to calecheamicin, given weekly, for refractory-relapse acute lymphocytic leukemia (R-R ALL). J Clin Oncol J Clin Oncol 30(30):6501, 6/2012.
16. Wang M, Fowler N, Wagner-Bartak N, Hagemeister F, Neelapu S, Fanale M, Younes A, Zhang L, Sun L, Badillo M, Bejarano M, Champlin R, Kwak L, Feng L, Byrne C, Bell N, Zeldis J, Romaguera J, Fayad L. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in a cohort of patients with DLBCL and grade 3 follicular lymphoma: a completed phase II clinical trial. 16th Congress of the European Hematology Association (EHA) (#237), 2012.
17. Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad LE, Liao Q, Edvardsen K, Lisby K, Moskowitz CH. A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT). Blood Blood (ASH Annual Meeting Abstracts)(118):957, 11/2011.
18. Samaneigo F, Wise J, Fayad LE, Fanale M, Hagemeister F, Sevaraj V, Goldenberg D, Kwak LK, Berkova Z. Anti-CD74 antibody hLL1 effects including bone marrow homing in lymphoma and chronic lymphocytic leukemia. Blood Blood (ASH Annual Meeting Abstracts)(118):1796, 11/2011.
19. Pham LV, Tamayo AT, Li C, Lee J, Fayad LE, Ford RJ. Chemo-Resistance in Diffuse Large Cell Lymphoma: Novel Drug Combinations Targeting NFAT/NF-Kb Growth/Survival/Chemo-Resistance Signaling Pathways in Validated Novel Experimental Systems. Blood Blood (ASH Annual Meeting Abstracts)(118):1428, 11/2011.
20. Dabaja BS, Phan J, Medeiros JL, Hagemeister FB, Chuang H, Fayad LE, Shihadeh F, Allen P, Wogan C, Rodriguez MA. Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(118):2695, 11/2011.
21. Bollard CM, Gottschalk S, Sheehan AM, Carrum G, Liu H, Pro B, Fayad LE, Younes A, Mims M, Gee AP, Brenner MK, Rooney CM, Heslop HE. Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins. Blood Blood (ASH Annual Meeting Abstracts)(118):956, 11/2011.
22. Vadhan-Raj S, Spasojevic I, Zhou X, Romaguera JE, Fanale MA, Fayad LE, Fowler NH, Huen A, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Younes A, Kwak LW. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. Blood Blood (ASH Annual Meeting Abstracts)(118):1613, 11/2011.
23. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Jabbour E, Garcia-Manero G, Ferrajoli S, Verstovsek S, Burger JA, Fayad LE, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood Blood (ASH Annual Meeting Abstracts)(118):2698, 11/2011.
24. O'Brien S, Thomas DA, Ohanian M, Jorgensen JL, Kebriaei P, Jabbour E, Rytting ME, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes JE, Fayad LE, Tarnai R, Wang SA, Champlin R, Advani AS, Kantarjian HM. Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL). Blood Blood (ASH Annual Meeting Abstracts)(118):875, 11/2011.
25. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad LE, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani S, van de Velde H, Qin X, Qi M, Cornfeld MJ, van Rhee F. Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,. Blood Blood (ASH Annual Meeting Abstracts)(118):3959, 11/2011.
26. Younes A, Copeland A, Fanale M, Fayad LE, Romaguera JE, Kwak LW, Neelapu S, Hagemeister F, Pro B, de Castro Faria S, Ji Y, Berry D, Buglio D, Medeiros J. Safety and efficacy of the novel combination of panobinostat (LBH589) and everloimus (RAD001) in relapsed/refractory hodgkin and non-hodgkin lymphoma. Blood Blood (ASH Annual Meeting Abstracts)(118):3718, 11/2011.
27. Thompson MA, Wei C, Moyer AM, Cunningham JM, Wang L, Fayad LE, Feng L, Rodriguez MA, Cabanillas F, Kantarjian HM, Kwak LW, Romaguera JE. Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up. Blood Blood (ASH Annual Meeting Abstracts)(118):3650 (#3650), 11/2011.
28. Dabaja BS, Phan J, Medeiros LJ, Chuang H, Fayad LE, Hagemeister F, Shihadeh FDA, Allen P, Rodriguez MA. Clinical implications of PET-negative residual disease at the completion of chemotherapy for diffuse large b-cell lymphoma. J Clin Oncol 29(15):2011, 6/2011.
29. Samaniego F, Hagemeister F, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Neelapu SS, Fayad LE, Orlowski RZ, Wang M, Lacerte L, Fowler N. High response rates with lenalidomide plus rituximab for untreated indolent b cell non-hodgkins lymphoma, including those meeting GELF criteria. J Clin Oncol 29(15):8030, 6/2011.
30. Fanale M, Vigil K, Lai CM, Feng L, Dong W, Younes A, Romaguera JE, Fayad LE, Hagemeister FB, Mulanovich V. Outcomes of HIV positive lymphoma patients treated in the highly active antiretroviral therapy (HAART) era. J Clin Oncol 29(15):2011, 6/2011.
31. Younes A, Kim S, Romaguera JE, Copeland A, de Castro Farial S, Kwak LW, Fayad LE, Hagemeister F, Fanale M, Lambert LM, Morariu-Zamfir R, Gordon L. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory b-cell lymphoma. J Clin Oncol, 6/2011.
32. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 11th International Conference on Malignant Lymphoma, Lugano, Switzerland, 6/2011.
33. Romaguera J, Wang M, Hagemeister F, Weaver P, Hartig K, Fanale M, Fayad LE, Fowler N, Orlowski R, Feldman T, Wagner-Bartak N, Smith J, Ford P, Kwak L, Goy A. Phase I-II study of bortezomib in combination with R-HCVAD and R-Methotrexate/ cytarabine (R-MA) in untreated mantle cell lymphoma (MCL). 16th European Hematology Conference, London, England 22(4):218, 6/2011.
34. Rodriguez MA, Durand JB, Astrow AB, Bury MJ, Fanale M, Hagemeister FB, Huang X, McLauglin P, Neelapu SS, Pro B, Kwak LW, Fayad LE, Romaguera JE, Younes A, Fisch M. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients >60 years old with untreated diffuse large b cell lymphoma (DLBCL). J Clin Oncol 29(15):8053, 6/2011.
35. Hainsworth JD, Arrowsmith E, McCleod M, Fayad LE, Hamid O, Davis L, Lin BK. Randomized phase II study of r-CHOP plus enzastaurin versus r-Chop in the first-line treatment of patients with intermediate and high-risk diffuse large b-cell lymphoma (DLBCL) - preliminary analysis. J Clin Oncol 29(15):8016, 6/2011.
36. Wang M, Fayad L, Wagner-Bartak N, Hagemeister F, Neelapu S, Finale M, Younes A, Cabanillas F, Zhang L, Champlin R, Kwak L, Feng L, Bell N, Zeldis J, Romaguera J. Oral lenalidomide plus 4 doses of rituximab induced prolonged remissions in relapsed/refractory mantle cell lymphoma: a completed phase I/II clinical trial. 11th International Conference on Malignant Lymphoma (ICML), Lugano, 2011.
37. Hamlin PA, Rodriguez MA, Noy A, Portlock CS, Straus D, McLaughlin P, Pro B, Fayad L, Hagemeister FB, Wegner B, Dumitrescu O, Pandit Tasker N, Moskowitz CH, Zelenetz AD. Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology (Blood) 116(21):1793, 11/2010.
38. Thomas DA, Faderl S, O'Brien S, Wierda WG, Garcia-Manero G, Verstovsek S, Konopleva M, Kadia T, Kornblau S, Fayad LE, Romaguera JE, Cortes JE, Kantarjian H. Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants. American Society of Hematology (Blood) 116(22):2831, 11/2010.
39. Okoroji GJ, de Padua Silva G, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad LE, Samaniego F, Fowler N, Champlin R, Hagemeister FB, Khouri I. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. American Society of Hematology (Blood) 3510 116(21):3510, 11/2010.
40. Fanale MA, Lai CM, McLaughlin P, Romaguera JE, Fayad LE, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak LW, Dong W, Reed V, Dabaja BS, Popat U, Younes A. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. American Society of Hematology (Blood) 116(2812), 11/2010.
41. Younes A, Copeland A, Fanale MA, Hagemeister F, Fayad LE, Pro B, Faria SC, Ji Y, Medeiros JL, Berry DA, Buglio D. Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma. American Society of Hematology (Blood) 116(3964), 11/2010.
42. Al-Ameri AM, Badoux X, Ferrajoli A, Wierda W, Fayad LE, Estrov Z, Bickel S, Keating MJ, O'Brien S. Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia. American Society of Hematology (Blood) 116(21):4488, 11/2010.
43. Raj SV, Hagemeister F, Fayad LE, Zhou X, ORoark SS, Ames K, Rodriguez MA, Fanale MA, Pro B, Johnson MM, McLaughlin P, Bueso-Ramos CE, Younes A, Kwak LW, Romaguera JE. Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study. American Society of Hematology (Blood) 116(21):1544, 11/2010.
44. Pro B, Perini G, Feng L, Romaguera J, Rodriguez MA, McLaughlin P, Hagemeister F, Fayad L, Kadia TM. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. J Clin Oncol (Meeting Abstracts) 28:8048, 6/2010.
45. Fowler M, McLaughlin P, Hagemeister F, Kwak L, Fanale M, Neelapu A, Fayad LE, Orlowski R, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol (Meeting Abstracts) 28:8036, 6/2010.
46. Perini G, Romaguera JE, Rodriguez MA, Pro B, Younes A, Fowler N, Hagemeister F, Samaniego F, Kwak LW, Fayad LE. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. J Clin Oncol (Meeting Abstracts) 28:8072, 6/2010.
47. Pozadzides JV, Perini G, Hess M, Romaguera JE, Hagemeister FB, McLaughlin P, Fayad LE, Khouri IF, Hosing C, Pro B. Prognosis and treatment of patients with peripheral T-cell lymphoma: The M. D. Anderson Cancer Center experience. J Clin Oncol (Meeting Abstracts) 28:850, 6/2010.
48. Manoukian G, Hagemeister F, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). J Clin Oncol (Meeting Abstracts) 28:8078, 6/2010.
49. Fowler N, McLaughlin P, Hagemeister FB, Kwak L, Fanale M, Neelapu S, Fayad LE, Pro B, Sergent C, White S, Samaniego F. A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:1714, 11/2009.
50. Wang M, Fayad LE, Hagemeister FB, Neelapu S, Samaniego F, McLaughlin P, Samuels B, Yi Q, Pro B, Fanale M, Shah J, Younes A, Bell N, Knight R, Zeldis JB, Cabanillas F, Kwak L, Romaguera JE. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:2719, 11/2009.
51. Dang NH, Smith MR, Offner F, Verhoef G, Johnson P, Rohatiner AZ, Kaufman JL, Gine E, Coiffier B, Czuczman MS, Foran J, Durrant S, Hua S, Vandendries ER, Fayad LE. Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:584, 11/2009.
52. Westin JR, Thompson MW, Cataldo V, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad LE, Fowler N, Kwak LW, McLaughlin P, Neelapu S, Pro B, Rodriguez MA, Shah JJ, Hagemeister FB. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. American Society of Hematology (Blood) 114(22):3922, 11/2009.
53. Westin JR, Thompson MA, Cataldo V, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Fanale M, Fayad LE, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez MA, Shah J, Hagemeister FB. Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. Blood (ASH Annual Meeting Abstracts) 114:3922, 11/2009.
54. Younes A, Copeland A, Romaguera JE, Fayad LE, Fanale M, de Castro Faria S, Medeiros LJ, Percy Ivy S. Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:3744, 11/2009.
55. Jones D, Windham J, Stewart B, Fayad LE, Rodriguez MA, Hagemeister FB. Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors. Blood (ASH Annual Meeting Abstracts) 114:968, 11/2009.
56. Hagenbeek A, Fayad LE, Delwail V, Rossi JF, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Gupta I, Arning M, Begtrup K, Schultz M, Bang B, Russell C, Czuczman MS. Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 114:935, 11/2009.
57. Thomas DA, Faderl S, O'Brien S, Wierda WG, Ravandi F, Garcia-Manero G, Verstovsek S, Kornblau S, Fayad LE, Cortes J, Kantarjian HM. Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update. Blood (ASH Annual Meeting Abstracts) 114:4099, 11/2009.
58. Copeland AR, Cao Y, Fanale M, Fayad LE, McLaughlin P, Pro B, Hagemeister F, Romaguera JE, Samaniego F, Rodriguez MA, Younes A. Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. Results of Long Follow up and Comparison to Institutional Historical Data. Blood (ASH Annual Meeting Abstracts) 114:1680, 11/2009.
59. Younes A, Gordon L, Kim S, Romaguera JE, Copeland AR, de Castro Farial S, Kwak L, Fayad LE, Hagemeister F, Fanale M, Lambert J, Bagulho T, Morariu-Zamfir R. Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 114:585, 11/2009.
60. Vadhan-Raj S, Fayad LE, Fanale M, Pro B, Rodriguez MA, Hagemeister F, Ames K, Bueso-Ramos CE, Zhou X, McLaughlin P, Fowler N, Shah J, Samaniego F, Younes A, Kwak L, Romaguera JE. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. Blood (ASH Annual Meeting Abstracts) 114:105, 11/2009.
61. Khouri IF, Harrell R, Valverde R, Korbling M, Manshouri T, Samuels B, Maadani F, Okoroji G, Bassett, Jr. R, Amin A, Anderlini P, De Lima M, Giralt S, Hosing C, Kebriaei P, Popat U, Qazilbash M, Ueno N, Stachowiak AM, Erwin B, Fayad LE, Pro B, Fowler N, McLaughlin P, Neelapu S, Younes A, Champlin R, Podoloff D. Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies. Blood (ASH Annual Meeting Abstracts) 114:868, 11/2009.
62. Fowler N, McLaughlin P, Kwak LW, Hagemeister F, Fanale M, Fayad L, Pro B, Samaniego F. Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma. J Clin Oncol 27(15S):445, 5/2009.
63. Jones D, Windham J, Stewart B, Fayad L, Rodriguez A, Hagemeister F. Differential JAK-STAT pathway activation in primary mediastinal large B-cell lymphoma produces distinct patterns of cytokine pathway response and predicted sensitivity to small molecule inhibitors. Blood, 2009.
64. Fanale MA, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. A phase I study of bortezomib in combination with ice (bice) in patient with relapsed/refractory classical hodgkin lymphoma. Blood 112(3048), 11/2008.
65. Kurzrock R, Fayad LE, Voorhees P, Furman RR, Lonial S, Borghaei H, Jagannath S, Sokol L, Cornfeld M, Qi M, Jiao T, Herring J, Qin X, van Rhee F,. A phase I study of CNTO 328, an anti-interleukin-6 monoclonal antibody in patients with B-cell non-hodgkin's lymphoma, multiple myeloma, or castleman's disease. Blood 112(1009), 11/2008.
66. Cataldo VD, Thompson MA, Toth BB, Sanjorjo P, Bekele BN, Jimenez C, Murphy WA, Huen AO, Arbuckle RB, Fanale M, Fayad LE, Fowler N, Kwak LW, McLaughlin PW, Neelapu SS, Pro B, Rodriguez AM, Shah J, Hagemeister FB. Bone loss in patients with previously untreated lymphoma: the effect of periodontal disease on the use of zoledronic acid. Blood 112(5297), 11/2008.
67. Van Rhee F, Fayad LE, Voorhees P, Furman RR, Borghaei H, Lonial S, Sokol L, Crawford J, Cornfeld M, Qi M, Herring J, Qin X, Kurzrock R. CNTO 328, a monoclonal antibody to interleukin-6, is active as a study agent in Castleman's disease: preliminary results of a phase I study. Blood 112(1008), 11/2008.
68. Wang M, Zhang L, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Pro B, Younes A, Miller S, Knight RD, Zeldis JB, Yi Q, Romaguera JE. Lenalidomide and rituximab are a promising combination in vitro, in vivo preclinically and in a phase I/II clinical trial in relapsed/refractory mantle cell lymphoma. Blood 112(3058), 11/2008.
69. Thomas DA, Kantarjian HM, Cortes J, Faderl S, Wierda WG, Ravandi F, Rodriguez MA, Fayad LE, O'Brien S. Long-term outcome after hyper-CVAD and rituximab chemoimmunotherapy for burkitt (BL) or burkitt-like (BLL) leukemia/lymphoma and mature B-cell acute lymphocytic leukemia (ALL). Blood 112(1929), 11/2008.
70. Mazloom A, Reed VK, Cabanillas F, Fayad LE, Pro B, Iyengar P, McLaughlin P, Urbauer DL, Dabaja BS. Marginal zone lymphoma: factors that affect the final outcome, a study of 275 patients. Blood 112(3764), 11/2008.
71. Samaniego F, Fanale M, Pro B, Hagemeister FB, McLaughlin P, Romaguera JE, Neelapu S, Rodriguez MA, Fayad LE, Younes A, Kwak L. Pentostatin, cyclophosphamide, and rituximab (PCR) achieve high response rates in indolent B-cell lymphoma without prolonged myelosuppression. Blood 112(835), 11/2008.
72. Romaguera JE, Fayad LE, McLaughlin P, Pro B, Rodriguez MA, Wang M, Weaver P, Hartig K, Kwak L, Feldman T, Smith J, Ford P, Goldberg S, Pecora A, Goy A. Phase I trail of bortezomib in combination with rituximab-hyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. Blood 112(3051), 11/2008.
73. Garg RJ, Wierda W, Fayad LE, Estrov Z, Bickel SM, O'Brien, S. Phase II study of dasatinib in patients with relapsed CLL. Blood 112(4197), 11/2008.
74. Romaguera JE, Fayad LE, Rodriguez AM, Hagemeister FB, Pro B, McLaughlin PW, Younes A, Samaniego F, Shah J, Weaver P, Hartig K, Cabanillas F, Kwak L, Kantarjian H, Wang M. Rituximab (R) + hypercvad alternating with r-methotrexate/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). Blood 112(833), 11/2008.
75. Fayad LE, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, Coiffier B, Hess G, Gine E, Advani Anjali, Offner F, Vandendries ER, Shapiro M, Dang NH. Safety and clinical activity of the anit-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymhoma: preliminary report of a phase 1/2 study. Blood 112(266), 11/2008.
76. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korblin M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogenic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 6/2008.
77. Rodriguez MA, Fanale M, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad LE, Durand J. Acitivity and toxicity of pegylated liposomal doxorubicin in combination regimen (DRCOP) for patients >60 years old with untreated diffuse large B cell lymphoma (DLBCL): A phase II study. J Clin Oncol 26(15S):725s (#20505), 5/2008.
78. Cultrera JL, Nunez RF, Romaguera JE, Hagemeister FB, Rodriguez MA, Fayad LE, Pro B. Early Fluro-2-deoxy-D-glucose positron emission tomography/computerized tomography (PET/CT) imaging as a tool for response assessment in T-cell non-Hodgkin's lymphoma (TCL): An update to a phase II study of HCVIDD alternated with methotrexate (MTX) and cytarabine (Ara-C). J Clin Oncol 26(15S):463s (#8538), 5/2008.
79. Zhou X, Huen A, Teegala S, Ji S, Fayad LE, Hagemeister FB, Vadhan-Raj S. Incidence and significant predicting factors for chemotherapy-induced severe thrombocytopenia in lymphoma patients. J Clin Oncol 26(15S):726s (#20519), 5/2008.
80. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad LE, Colffier B, Morchhauser F. Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. J Clin Oncol 26(15S):142s (#3043), 5/2008.
81. Suh GK, McLaughlin P, Romaguera JE, Hagemeister FB, Pro B, Khouri IF, Samaniego F, Rodriguez MA, Fayad LE, fENG l, Younes A. Long-term follow-up of pacitaxel and topotecan plus rituximab (TTR) for patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 26(15S):478s (#8599), 5/2008.
82. Shah N, Cabanillas F, Feng L, McIntyre B, McLaughlin P, Rodriguez MA, Romaguera JE, Younes A, Hagemeister FB, Kwak L, Fayad LE. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin's lymphomas. J Clin Oncol 26(15S):475s (#8589), 5/2008.
83. Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad L, Colffier B, Moschhauser F. Acitivity of Veltuzumab, a Second-Generation Humanized Anti-CD20 MAB, in Laboratory and Clinical Studies. Annals of Oncology 19(4):iv130 (#144), 2008.
84. Berkova Z, Maeng H, Wang S, Wang S, Wise J, Hawke D, Campbell M, Fayad L, Kwak L, Samaniego F. CD74 Associates with FAS and Inhibits FAS-Mediated Apoptotic Signaling. Annals of Oncology 19(4):iv169 (#287), 2008.
85. Wang M, Fayad L, Hagemeister F, Neelapu S, Samuels B, Samaniego F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera J. Lenalidomide in Combination with Rituximab is Effective with Manageable Toxicity in a Phase I/II study in Relapsed/Refractory Mantle Cell Lymphoma. Annals of Oncology 19(4):iv174 (#306), 2008.
86. Samaniego F, Fanale M, Pro B, Hagemeister F, McLaughlin P, Romaguera J, Neelapu S, Rodriguez A, Fayad L, Younes A, Kwak L. Pentostatin Combined with Cyclophophamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lymphoma. Annals of Oncology 19(4):iv182 (#334), 2008.
87. Romaguera JE, Pro B, Fayad L, McLaughlin P, Wang M, Weaver P, Hartig K, Hagemeister F, Rodriguez MA, Younes A, Samaniego F, Fanale M, Kwak L, Feldman T, Goy A. Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. Annals of Oncology 19(4):iv214 (#444), 2008.
88. Hamlin PA, Moskowitz CH, Wegner B, Noy A, Gerecitano J, Palomba ML, Portlock C, Straus D, Pro B, Fayad L, Rodriguez A, Zelenetz AD. Sequential RCHOP and YTTRIUM-90 Ibritumomab Tiuxetan (RIT) is a highly effective regimen for High Risk Elderly Patients with Untreated DLBCL. Annals of Oncology 19(4):iv100 (#054), 2008.
89. Zhou X, Huen A, Teegala A, Ji Y, Fayad LE, Hagemeister F, Vadhan-Raj S. Higher Incidence of Venous Thromboembolism Is Associated with Initial Cycles of Chemotherapy in Lymphoma Patients: Creatinine and Hemoglobin as Key Risk Factors. Blood 110(11):66B, 11/2007.
90. Younes A, Pro B, Fanale M, McLaughlin P, Neelapu S, Fayad LE, Wedgwood A, Buglio D, Patterson T, Dubay M, Li Z, Martell RE, Ward MR, Bociek RG. Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL). Blood 110(11):756a, 11/2007.
91. Wang M, Fayad LE, Hagemeister F, Neelapu S, Samuels B, Samanigo F, Pro B, Yi Q, Bell N, Byrne C, Weaver P, Hartig K, Knight R, Zeldis J, Kwak L, Romaguera JE. Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL). Blood 110(11):755a, 11/2007.
92. Thomas D, Kantarjian H, Cortes J, Faderl S, Ravandi-Kashani F, Wierda W, Rodriguez MA, Fayad LE, O’Brien S. Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukmia (B-ALL). Blood 110, 11/2007.
93. Tam CS, Ledesma C, Korbling M, Fayad LE, Wang M, Alousi A, Hosing C, Kebriaei P, Rondon G, Giralt SA, Anderlini P, Popat U, Couriel D, Pro B, Samuels B, Hagemeister F, Champlin RE, Khouri I. Non-Myeloablative Allogeneic Stem Cell Transplantation (NMT) Overcomes the Adverse Effects of Treatment Resistance and High Beta-2-Microglobulin in Patients with Mantle Cell Lymphoma (MCL): An Analysis of 123 Transplantations at the MD Anderson Cancer Center. Blood 110(11):149a, 11/2007.
94. Khouri I, Saliba R, Korbling M, Hosing C, Fayad LE, Lee MS, Samaniego F, Samuels BI, Couriel D, Hagemeister F, McLaughlin P, Champlin RE. Nonmyeloablative Allogeneic Transplantation (NMT) for Relapsed Follicular Lymphoma (FL): Continuous Complete Remission with Longer Follow-Up. Blood 110(11):150a, 11/2007.
95. Rodriguez MA, Fanale M, Hagemeister F, McLaughlin P, Pro B, Romaguera JE, Kwak L, Fayad LE, Huang X, Durand JBE. Phase II Study of RCHOP with Pegylated Liposomal Doxorubicin (DRCOP) for Patients > 60 Years Old with Untreated Diffuse Large B Cell Lymphoma (DLBCL). Blood 110(11):187B, 11/2007.
96. Pro B, Fayad LE, Romaguera JE, Fanale M, Younes A, Hagemeister F, Samaniego F, McLaughlin P, Rodriguez MA, Kwak L, Dang NH. Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma. Blood 110(11):1013A, 11/2007.
97. Fayad LE, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Neelapu S, Kwak L, Romaguera JE, Rodriguez MA. R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years. Blood 110, 11/2007.
98. Wedgwood AR, Fanale M, Fayad LE, McLaughlin P, Hagemeister F, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, Younes A. Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2–3 Cycles of Therapy. Blood 110(11):71a, 11/2007.
99. Fanale M, Fayad LE, Pro B, Samaniego F, Zachariah G, Nunez CA, Ji Y, Younes A. Safety and Efficacy of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma. Blood 110(11):198B, 11/2007.
100. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister F, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone. Blood 110, 11/2007.
101. Alousi AM, Hosing C, Saliba RM, Valverde RB, Maadani F, Korbling M, Okoroji GJ, Fayad LE, Stachowiak AM, Erwin WD, Anderlini P, de Lima MJ, Giralt SA, Popat UR, Kebriaei P, Ueno NT, McLaughlin P, Pro B, Wang M, Rodriguez MA, Hagemeister F, Macapinlac HA, Podoloff DA, Champlin RE, Khouri I. Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status. Blood 110(11):191a, 11/2007.
102. Wang S, Wang S, Maeng H, Young DP, Prakash OM, Fayad LE, Younes A, Samaniego F. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 109, 3/2007.
103. Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, Knight R, Zeldis J, Kwak L, and Romaguera J. A Phase I/II Study of Lenalidomide (Len) in Combination with Rituximab (R) in Relapsed/Refractory Mantle Cell Lymphoma (MCL) with Early Evidence of Efficacy. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 25(18s):[8030], 2007.
104. Falchook GS, Dhillon N, Moulder S, Duvic M, Ng C, Hong D, Camacho L, Lim J, Wang M, Fayad L, and Kurzrock R. Age-Stratified Phase I Trial of a Combination of Bortezomib, Gemcitabine, and Liposomal Doxorubicin in Patients with Advanced Malignancies. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):14087, 2007.
105. Lenihan DJ, Massey MR, Baysinger K, Steinert D, Fayad L, Yusuf SW, Chiu A, Durand A, and Yeh ET. Early Detection of Cardiotoxicity During Chemotherapy Using Biomarkers. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):19521, 2007.
106. Huen A, Romaguera JE, Fayad LE, Teegala SR, Ji Y, and Vadhan-Raj S. Increased Toxicity Associated with Delayed Clearance of Methothrexate (MTX) in Patients with Lymphoma Receiving High-Dose MTX. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):[19578], 2007.
107. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon M, Coleman M, Horne H, Teoh N, Wegner WA, and Goldenberg DM. Low Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20), in Refractory or Recurrent NHL: Phase I/II Results. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8032, 2007.
108. Rodriguez MA, Temple S, Fayad L, Hagemeister F, McLaughlin P, Romaguera J, and Cabanillas F. Predictive Value for Survival of a Risk Model of Two Serological Markers, Beta-2-Microglobulin (B2M) and Lactic Dehydrogenase (LDH), in Diffuse Large Cell Lymphoma (DLCL). J Clin Oncol 25(18s):10599, 2007.
109. Fayad L, Temple S, Pro B, Hagemeister F, Cabanillas F, Samaniego F, McLaughlin P, Wang M, Kwak L, Romaguera J, and Rodriguez MA. R-HCV AD/R-MTX-ARAC is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features: M.D. Anderson Experience in 40 Patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8058, 2007.
110. Teegala SR, Zhou X, Huen A, Ji Y, Fayad LE, Romaguera JE, and Vadhan-Raj S. Risk Factors for Neutropenic Fever in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Onco 25(18s):19616, 2007.
111. Zhou X, Teegala SR, Huen A, Ji Y, Fayad LE, Romaguera JE, Hagemeister FB, and Vadhan-Raj S. Risk Factors for Severe Anemia Requiring Red Blood Cell Transfusions in Lymphoma Patients Receiving Chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):19537, 2007.
112. Kornblau SM, Jackson CE, Worthing A, Faderl S, Beran M, Fayad L, Ravhandi-Kashani F, Borthakur G, Gale R, Vertovsek S. A phase I trial of a novel organic arsenic S-dimethylarsino-glutathione (ZIO-101). J Clin Oncol 24 (18s):664s, 2006.
113. Pro B, Fayad L, Romaguera J, Hagemeister FB, Samaniego F, McLauhglin P, Rodriguez AM, Kwak L, Walker P, Dang N. A phase II of HCVDDoxil alternated with methotrexate-cytarabine in patients with newly diagnosed T-cell lymphoma. J Clin Oncol 24 (18s):103s, 2006.
114. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu S, Fayad L, Wedgwood A, Dubay M, Backstrom J, and Martell RE. A Phase II Study of a Novel Oral Isotype-Selective Histone Deacetylase(HDAC) Inhibitor in Patients with Relapsed or Refractory Hodgkin Lymphoma. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25(18s):8000, 2006.
115. Forero-Torres A, Cohen P, Cheson BD, Robinson KS, La Casce AS, Fayad L, Camacho ES, Williams ME, Van de Jagt RH, Friedberg JW. A phase II study of Bendamustine for rituximab refractory B-cell Non-Hodgkin’s lymphoma. ESMO, 2006.
116. Pro B, Nunez RF, Romaguera J, Rodriguez MA, Hagemeister, F, and Fayad L. Achievement of FDG-PET Negativity Does Not Predict Durable Responses in T-Cell Lymphoma. Blood 108(11):[2404], 2006.
117. Fayad L and Cannata J. Adult Langerhans’ Cell Histiocitosis (LCH): A Single Institution Experience. Blood 108(11):[3890], 2006.
118. Romaguera JE, Fayad L, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang L, Kantarjian HM, Beasley V, Medeiros LJ, Katz RL, and Cabanilla F. Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A). Blood 108(11):[2749], 2006.
119. Fayad L, Patel H, Verhoef G, Czuczmar M, Foran J, Gine E, Rohatiner A, Smith MR, Shapiro M, and Advani A. Clinical Activity of the immunoconjugate CMC-544 in B-Cell malignancies: Cohort of a Phase I Study. Blood 108(11):[2711], 2006.
120. VanRhee F, Fayad L, Borghaei H, Voorhees PM, Orlowski RZ, Furman RR, Zaki M, Prabhakar U, Jiao T, Lihou C, Garay CA, and Kurzrock R. CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) – Prelimi Subjects with Castleman’s Disease from a Phase 1 Study in Selected Hematolog Malignancies. Blood 108(11):[2728], 2006.
121. Khouri IF, Saliba RM, Hosing C, Valverde R, Erwin WD, Fayad L, Maadani F, Korbling MJ, Okoroji GJ, Stachowiak AM, Samuels BI, Anderlini P, Couriel DR, de Lima M, Giralt S, Popat U, kebriaei P, Ueno N, Qazilbash MH, McLaughlin P, Hagemeister FB, Younes A, Podoloff DA, and Champlin RE. Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed and Non-Hodgkin’s Lymphoma (NHL). Blood 108(11):[315], 2006.
122. Fayad L, Overman M, Pro B, McLaughlin P, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, kwak L, and Rodriguez MA. Favorable Results of Rituximab in Combination with CHOP in the Front-Line Treatment of Follicular Lymphoma Grade 3. Blood 108(11):[2770], 2006.
123. Teegala S, Zhou X, Huen A, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, and Vadhan-Raj S. High Incidence of Venous Thromboembolism in Patients with Lymphoma Receiving Chemotherapy: Assessment of Risk Factors. Blood 108(11):[4103], 2006.
124. Huen A, Zhou X, Teegala S, Ji Y, Fayad L, Romaguera JE, Hagemeister FB, Vadhan-Raj S. Incidence and Risk Factors for Severe Thrombocytopenia in Lymphoma Patients Receiving Chemotherapy. Blood 108(11):[3994], 2006.
125. Samaniego F, Fayad L, Pro B, McLaughlin P, Rodriguez MA, Hagemeister FB, Fanale M, Neelapu S, Younes A, and Kwak L. Pentostatin Combined with Cyclophosphamide, and Rituximab Induces High Response Rates in Patients with Untreated Indolent B-Cell Lymphoma. Blood 108(11):[4722], 2006.
126. Kurzrock R, Voorhees P, Fayad L, Orlowsky R, Van Thee F, Furman R, Borghaei H, Zaki MH, Prabhakar U, Garay C. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in subjects with hematology malignancies. J Clin Oncol 24(18s):664s, 2006.
127. Fayad L, Liebmann J, Modiano M, Cohen G, Pro B, Romaguera J, and Stromatt S. Results of a Phase I/II Trial of Pixantrone in combination with Fludarabine, Dexamethasone, and Rituximab in the Treatment of Patients with Relapsed Refractory Indolent Non-Hodkin’s Lymphoma (NHL). Blood 108(11):[2758], 2006.
128. Younes A, Fayad L, Goy A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, Medeiros LJ, Wedgwood A, and Fanale M. Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups. Blood 108(11):[2742], 2006.
129. Kadia T, Fayad L, Rodriguez MA, McLaughlin P, and Pro B. Retrospective Review of Angiommunoblastic T-Cell Lymphoma: The MD Anderson Cancer Experience. Blood 108(11):[4690], 2006.
130. Morschhauser F, Leonard JP, Fayad L, Coiffier B, Schuster S, Dyer MJS, Petillon MO, Coleman M, Bahkti A, Horen H, Xu L, Teoh N, Wegener W, and Goldenberg DM. Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results. Blood 108(11):[2719], 2006.
131. Faderl S, Ferrajoli A, Wierda WG, O’Brien S, Ravandi-Kashani F, Fayad L, Thomas D, Kantarjian H, Browning ML, and Keating MJ. The Combination of Alemtuzumab [Continuous Intravenous Infusion (civ) Followed by Subcutaneous Injection (sc)] Plus Rituximab Has Activity in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL). Blood 108(11):[2827], 2006.
132. Younes A, Pro B, Fayad L, Dang N, Romaguera J. (Velcade) for the treatment of relapsed classical Hodgkin’s lymphoma. Ann Oncol 16(Suppl 5):v210 (#593), 2005.
133. Fayad L, Liebman J, Mediano M, Cohen G, Pro B, Romaguera J, Countouridis A, Lymboura M, Comis S, Laffranchi B. A phase I/II trial of pixantrone combined with fludarabine (FL), dexamethasone (DEX) and rituximab (FPD-R) for treatment of recurrent indolent B-cell non-Hodgkin’s lymphomas. . Ann Oncol 16(Suppl 5):v156 (#403), 2005.
134. Pro B, Leber B, Smith MR, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. A Phase II Trial of Oblimersen Sodium (G3139) plus Rituximab for Treatment of Patients with Recurrent B-cell Non-Hodgkin’s Lymphoma. . Ann Oncol 16(Suppl 5):v68 (#103), 2005.
135. Younes A, Fayad L, Romaguera JE, Pro B, and Wang M. ABVD with Pegfilgrastim (Neulasta) Support in Newly Diagnosed Hodgkin Lymphoma: Long-Term Safety and Efficacy Results of a Phase-II Study. Blood 106(11):[4790], 2005.
136. Khouri IF, Saliba RM, Hosing CM, Acholonu SA, Fayad LE, Korbling MJ, Saenz C, Pro B, Samuels BI, de Lima MJ, Giralt SA, Younes A, McLaughlin P, and Champlin RE. Autologous Stem Cell (AUTO) vs Non-Myeloablative Allogeneic Transplantation (NMT) after High-Dose Rituximab (HD-R) -Containing Conditioning Regimens for Relapsed Chemosensitve Follicular Lymphoma (FL). Blood 106(11):[48] 19a, 2005.
137. Friedberg JW, Cohen P, Cheson BD, Robinson KS, Forero-Torres A, Fayad L, La Casce AL, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver J, and Benaim E. Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01). Blood 106(11):[229] 70a, 2005.
138. Soriano AO, Thompson M, Romaguera J, Rodriguez MA, Hagemeister FB, Fayad L, Admirand JH, and Pro B. Follicular Dendritic Cell Sarcoma (FDCS): A Rare and Incurable Disease. Blood 106(11):[3892], 2005.
139. Younes A, Fayad L, Pro B, Goy A, Romaguera JE, Hagemeister FB, and McLaughlin P. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. Blood 106(11):[1498] 431a, 2005.
140. Romaguera JE, Fayad LE, Wang M, Cabanillas F, Hagemeister F, McLaughlin P, Rodriguez A, Younes A, Neelapu S, Goy AH, Beasley V, and Kwak L. High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A). Blood 106(11):[2446] 688a, 2005.
141. Romaguera J, Fayad L, Rodriguez M, Hagemeister F, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris A, Dang N, MedeirosJ, Katz,R, Gagneja H, Samuels B, Cabanillas F. High rates of Failure-Free Survival (FFS) and Overall Survival (OS) in untreated Mantle Cell lymphoma(MCL) after Rituximab plus HyperCVAD (R-HCVAD) alternating with rituximab plus High-Dose Methotrexate-Cytarabine (R-M/A). . Ann Oncol 16(Suppl 5):v95 (#197), 2005.
142. Pro B, Cabanillas F, Fayad L. High-serum b2 microglobulin is an important independent prognostic factor for disease progression in patients with follicular lymphoma. . Ann Oncol 16(Suppl 5):v149 (#381), 2005.
143. Fayad L, Dang J, Keating M. Hodgkin’s disease variant of Richter’s syndrome, an update of the M. D. Anderson experience. . Ann Oncol 16(Suppl 5):v114 (#262), 2005.
144. Dang NH, McLaughlin P, Fayad L, Romaguera J, Hagemeister F, Younes A, Neelapu S, Samaniego F, Jones D, Walker PL, Rodriguez MA, Kwak L, and Pro B. Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma. Blood 106(11):[3349] 936a, 2005.
145. Khouri IF, Saliba RM, Lee MS, Okoroji GJ, Fayad L, Maadani F, Hosing C, Samuels B, Giralt S, de Lima M, Pro B, Younes A, McLaughlin P, Kwak L, and Champlin RE. Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease. Blood 106(11):[44] 19a, 2005.
146. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, dang N, Samaniego F, Rodriguez M, Fayad L. Paclitaxel plus Topotecan plus Rituximab (TTR): An Effective Salvage Program for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma (NHL). Ann Oncol 16(Suppl 5):v101 (#220), 2005.
147. Dang NH, Pro B, Hagemeister F, Samaniego F, Jones D, Rodriguez M, Goy A, Romaguera J, Walker PL, Younes A, Neelapu S, Kwak L, and Fayad L. Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma. Blood 106(11):[3350] 936a, 2005.
148. Pro B, Smith MR, Leber B, Younes A, Fayad LE, Hagemeister F, McLaughlin P, Rodriguez MA, Caddick Y, Zwiebel JA. Phase II study of Oblimersen Sodium and Rituximab in Patients with Recurrent B-cell Non-Hodgkin’s Lymphoma. J Clin Oncol 23(16S):587S (#6611), 2005.
149. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera J, Younes A, and Cabanillas F. Phase II Study of Sphingosomal Vincristine in CHOP+/ – Rituximab for Patients with Aggressive Non-Hodgkin’s Lymphoma (NHL): Promising 3 Year Follow-Up Results in Elderly Patients. Blood 106(11):[943] 277a, 2005.
150. Jabbour E, Hosing C, Pro B, Khouri I, Fayad L. Positive Pre-transplant PET/Ga67 (Ga) predicts poor outcome in refractory and relapse Hodgkin’s lymphoma. Ann Oncol 16(Suppl 5):v121 (#285), 2005.
151. Jabbour E, Hosing C, Pro B, Champlin R, Khouri I, Romaguera J, Fayad LE. Pre transplant positive PET/Gallium scans predict poor outcome in relapsed/refractory Hodgkin’s lymphoma (HL). Proceedings ASCO. J Clin Oncol 23(16S):562S (#6509), 2005.
152. Fayad L, Romaguera J, hart S, Younes A, Pro B, Hagemeister F, McLaughlin P, Dang N, Pretti A, Sarris A, Gil F. Report of a phase II study of sphingosomal vincristine (SV) in patients with relapsed or refractory Hodgkin’s disease. J Clin Oncol 23(16S):591S (#6624), 2005.
153. Thompson MA, Pro B, Sarris A, Hagemeister FB, Goy A, Bleyer A, Cabanillas F, Samaniego F, and Fayad LE. Results of a Phase II Study of 506U78 (Nelarabine) in Refractory Indolent B-Cell or Peripheral T-Cell Lymphoma. Blood 106(11):[2681] 753a, 2005.
154. Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Dang N, Goy A, Romaguera J, Pro B, Beasley V, Cabanillas F, and Rodriguez M. Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL). Blood 106(11):[941] 277a, 2005.
155. Younes A, McLaughlin P, Fayad L, Goy A, Medeiros L, Pro B, Romaguera J, Rodriguez M, Samaniego F, Dang N, et al. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin’s lymphoma: A novel combination program targeting the cancer cells and the reactive B-cells in the microenviroment. . Ann Oncol 16(Suppl 5):v196 (#545), 2005.
156. McLaughlin P, Liu NS, Grimmm E, Fayad L, Hagemeister FB, Nunez G, Romaguera J, Goy A, Samaniego F, Wang M, Ayala A, Lee BN, Reuben JM, Kwak L, Rodriguez MA. Rituximab plus GM-CSF (Leukineä) for Indolent Lymphoma. Ann Oncol 16(Suppl 5):v68 (#104), 2005.
157. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Safety and efficacy of single fixed dose pegfilgrastin (Neulasta) in chemotherapy regimens given every 14 days: Results of ABVD plus pegfilgrastin in patients with Hodgkin’s lymphoma. . Ann Oncol 16(Suppl 5):v196 (#546), 2005.
158. Younes A, McLaughlin P, Fayad LE, Goy A, Romaguera JE, Pro B, Rodriguez MA, Samaniego F, Kwak L, Neelapu S, and Medeiros J. Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab. Blood 106(11):[1499] 431a, 2005.
159. McLaughlin P, Rodriguez M, Hagemeister F, Romaguera J, Sarris A, Younes A, Dang N, Goy A, Samaniego F, Hess M, Lee M, Medeiros J, Fayad L, Pro B, Jiang Y, Ayala A, Cabanillas F. Stage IV indolent Lymphoma: A randomized trial of concurrent vs. sequential FND (fludarabine, mitoxantrone, dexamethasone) and rituximab with interferon maintenance. Ann Oncol 16(Suppl 5):v109 (#247), 2005.
160. Cohen P, Cheson B, Friedberg J, Robinson KS, Foran J, Fayad L, Tulpule A, Bessudo A, van der Jagt R, Suster MS, Multani PS. The novel alkylator Bendamustine HCL is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity. . J Clin Oncol 23(16S):576S (#6564), 2005.
161. Georgakis G, Li Y, Rassidakis G, Fayad L, Medeiros L, Younes A. Therapeutic inhibition of heat schock protein-90 function in Hodgkin’s lymphoma. Ann Oncol 16(Suppl 5):v215 (#6074), 2005.
162. Fayad L, Pro B, Liu Q, Hess M, Hagemeister F, Romaguera J, Samaniego F, Cabanillas F, Rodriguez A, Younes A, Wang M, and McLaughlin P. Time to Treatment Failure (TTF) and FLIPI Correlate Well with Survival and Are Independent Variables in Stage IV Indolent Follicular Lymphomas (IFL). Blood 106(11):[933] 274a, 2005.
163. Tsimberidou AM, O’Brien S, Kantarjian H, Koller C, Hagemeister F, Fayad L, Lerner S, and Keating MJ. Transformation of Chronic Lymphocytic Leukemia into Hodgkin’s Disease The M D Anderson Cancer Center Experience. Blood 106(11):[976] 287a, 2005.
164. Khouri I, Saliba R, Lee M, Okoroji GJ, Fayad L, Acholonu S, Maadani F, Hosing C,Younes A, McLauhglin P, Champlin R. Transplant Lite with rituximab-containing conditioning regimens for Non-Hodgkin’s Lymphomas (NHL): An Update. Ann Oncol 16(Suppl 5):v101 (#218), 2005.
165. Camboni G, Fayad L, Tulpule A, Modiano M, Espina BM, Cabanillas F, Levine AM. A phase I/II of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin’s lymphoma (NHL). J Clin Oncol 23:578 (#6590), 2004.
166. Dang NH, Pro B, Hagemeister FB, Jones D, Samuels B, Rodruiguez MA, Goy A, Romaguera JE, Walker P, Kwak L, Fayad L. Interim Analysis of a Phase II study of Dinileukin Diftitox (ONTAK) for relapsed/refractory T-cell Non-Hodgkin’s lymphoma. . Blood 104(11):722a (#2641), 2004.
167. Younes A, Fayad L, Romaguera J, Pro B, Goy A, Dang N, Wang M. Long-term safety and efficacy of single administration of a fixed dose peffilgrastin (Neulasta) in inducing neutrophil count recovery after ABVD chemotherapy in patients with Hodgkin’s lymphoma. . Blood 104(11):245b (#4646), 2004.
168. Fayad L, Liebmann J, Modiano M, Cohen GI, Pro B, Romaguera J, Davite C, Lymboura M, Comis S, Laffranchi B. Preliminary results of a Phase I/II trial of BBR-2778 (pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatments of patients with relapsed/refractory indolent non-Hodgkin’s lymphoma. Blood 104(11):373a (#1324), 2004.
169. Samaniego F, Wang S, Young D, Fayad L, Wang S. Simian Virus 40 DNA sequences in non-Hodgkin’s lymphoma. J Clin Oncol 23:581 (#6604), 2004.
170. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP +/- rituximab is a promising new treatment for patients with high-risk untreated aggressive non-Hodgkin’s lymphoma (NHL): Follow-up results of a phase II study. Blood 104(11):234b (#4602), 2004.
171. Rodriguez MA, Dang NH, Fayad L, Goy A, Hagemeister FB, McLaughlin P, Pro B, Romaguera JE, Younes A, Cabanillas F. Sphingosomal Vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin’s lymphoma (NHL): Follow-up of a phase II study. . J Clin Oncol 23:745 (#8080), 2004.
172. Goy A, Younes A, McLaughlin P, Pro B, Romaguera J, Hagemeister F, Fayad L, Trehu EG, Schenkein D, Rodriguez MA. Update on a phase (ph) 2 tudy of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin’s lymphoma (NHL). . J Clin Oncol 23:575 (#6581), 2004.
173. Liu NS, Grimm E, Poindexter N, Rodriguez MA, Hagemeister F, Pro B, Fayad LE, Lee BN, Reuben JM, McLaughlin P. [1495] Antibody Dependent Cellular Cytotoxicity and Natural Killer Cell Activity in Patients with Recurrent Indolent Lymphoma Receiving Rituximab in Combination with GM-CSF. Blood 102(11):411a (#1495), 2003.
174. Dang N, Hagemeister F, Fayad LE, Pro B, McLaughlin P, Romaguera JE, Samaniego F, Goy A, Wang M, Walker PL, Samuels B, Jones D, Rodriguez MA. Analysis of a Phase II Study of Denileukin Diftitox (ONTAK) for B and T-Cell Non-Hodgkins Lymphoma. Blood 102(11):303b (#4935), 2003.
175. Younes A, Pro B, Goy A, Fayad L, Romaguera J. Gemcitabine Plus Rituximab Therapy of Patients with Relapsed and Refractory Classical Hodgkin Disease. Depletion of Benign B-Cells from HD Microenvironment by Rituximab May Enhance the Activity of Gemcitabine. Blood 102(11):412a (#1500), 2003.
176. Pro B, Smith MR, younes A, Dang NH, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Rodriguez MA, Samuels B, Arredondo Y, Frankel SR, Zwiebel JA. Genasense (BCL-2 Antisense) plus Rituximab is active in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma. . Submitted to ASH 2003, 2003.
177. Khouri I, Saliba R, Acholonu S, Okoroji G, Hosing C, Fayad LE, Couriel DR, Pro B, Giralt S, Andersson B, Younes A, McLaughlin P, Champlin RE. Improved Outcome with High-Dose Rituximab (HD-R) with G/GM-CSF and Autologous Stme Cell Transplantation (ASCT) fro Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL): The Impact of Histologies of follicular (FL) Origin. Blood 102(11):735a (#2716), 2003.
178. Levine A, Fayad L, Modiano M, Camboni G, Cabanillas F. Phase I study of BBR-2778 in BSHAP for relapsed aggressive non-Hodgkin's lymphoma. . Exp Hematol 31(Suppl 1):110, 2003.
179. Levine AM, Fayad L, Modiano M, Camboni G, Cabanillas F. Phase I study of Pixantrone in BSHAP for relapsed non-Hodgkin’s Lymphoma. . Proceedings of the International Society of Experimental Hematology, France (#154), 2003.
180. Pro B, Cabanillas F, Dang NH, Fayad LE, Goy A, McLaughlin P, Rodriguez MA, Romaguera JE, Samaniego F, Wu HH, Hess M, Gold DL, Hagemeister F. Prognostic Factors in Follicular Lymphoma: The Importance of Beta-2 Microglobulin. . Blood 102(11):281b (#4845), 2003.
181. Levine AM, Fayad LE, Tulpule A, Modiano M, Espina BM, Camboni G, Cabanillas F. Results of a Phase I/II Trial with BBR-2778 (Pixantrone), Methylprednisolone, Cisplatin, and Cytosine Arabinoside (BSHAP) in Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma (NHL). Blood 102(11):640a (#2364), 2003.
182. Younes A, McLaughlin P, Goy A, Medeiros LJ, Jones D, Fayad LE, Abruzzo L, Pro B. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease: A Novel Combination Program Targeting the Cancer Cells and the Microenvironment. Blood 102(11):27a (#83), 2003.
183. Younes A, Fayad LE, Pro B, McLaughlin P, Hagemeister FB, Mansfield P, Clayman G, Medeiros LJ, Lewis J, Srivastava P. Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low-grade lymphoma. Proceedings of ASCO 22:2294, 2003.
184. Younes A, Fayad LE, Romaguera JE, Pro B, Dang N, Wang M. Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil Count Recovery after 170 Consecutive Doses of ABVD Chemotherapy in Patients with Hodgkin Lymphoma: Safety of Pegfilgrastim with q14-Day Chemotherapy Regimens. Blood 102(11):637a (#2352), 2003.
185. Liu Q, Fayad LE, Hagemeister F, Rodriguez MA, Younes A, Pro B, Verstovsek S, Cabanillas F, Tsimberidou A, Hess M, Ayala A, Clemons M, McLaughlin P. Stage IV Indolent Lymphoma: 25 Years of Treatment Progress. Blood 102(11):398a (#1446), 2003.
186. Younes A, McLaughlin P, Romaguera J, Hagemeister F, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L. Taxol Plus Topetecan Plus Rituximab (TTR) with G-CSF Support: An Effective Salvage Program for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgekin Lymphoma (NHL) Who Failed CHOP-Like and Platinum-Based Therapy. Blood 102(11):142a (#489), 2003.
187. Rodriguez MA, Sarris A, East K, Dang N, Fayad LE, Goy A, Hagemeister F, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Younes A, Cabanillas F. A Phase II study of Liposomal Vincristine in CHOP with Rituximab for Patients with Untreated Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL): A Safe and Effective Combination. Blood 100:338, 2002.
188. Younes A, McLaughlin P, Pro B, Hagemeister F, Fayad LE, Romaguera JE. Activity of Oxaliplatin in Patients with Relapsed and Refractory Non-Hodgkin Lymphoma. Blood 100:4722, 2002.
189. Younes A, McLaughlin P, Hagemeister FB, Pro B, Samaniego F, Romaguera JE, Dang NH, Fayad L, Goy A, Rodriguez MA, Cabanillas F. Addition of Rituximab to Taxol plus Topotecan (TTR) improves response rate and complete remission rate in patients with relapsed/refractory aggressive B-cell lymphoma. Annals of Oncol 13(Suppl 2):246, 2002.
190. Younes A, Pro B, Hagemeister F, Rodriguez MA, McLaughlin P, Fayad LE, Goy A, Cabanillas F. Efficacy of Single Administration of a Fixed Dose Pegfilgrastim (Neulasta) in Inducing Neutrophil count Recovery after Paclitaxel Plus Topotecan Chemotherapy in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma. Blood 100:2868, 2002.
191. Hagemeister F, McLaughlin P, Clemons M, Rodriguez MA, Fayad L, Romaguera J, Pro B, Goy A, Samaniego F, Dang NH, Cabanillas F. FND (Fludarabine, Mitoxantrone, Dexamethasone)- R(Rituximab) for Patients (pt) with Relapsed (Rel) or Chemotherapy Resistant (CTR) Indolent Lymphomas (IL): A Preliminary Report. Blood 100:4760, 2002.
192. Khouri IF, Saliba R, Hosing C, Kôrbling M, Younes A, Romaguera J, Fayad L, Cabanillas F, Champlin RE. Long-term follow-up of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma. Annals of Oncol 13(Suppl 2):262, 2002.
193. Romaguera J, Cabanillas F, Dang N, Goy A, Fayad LE, Hagemeister FB, McLaughlin P, Pro B, Rodriguez MA, Samaniego F, Sarris AH, Younes A, Medeiros LJ, Gagneja HK. Mantle Cell Lymphoma (MCL). Update on results after R-HCVAD without stem cell transplant (SCT). Annals of Oncol 13(Suppl 2):024, 2002.
194. Pro B, Romaguera J, Macapinlac H, Fayad LE, Dang N, Samaniego F, Goy A, Rodriguez MA, McLaughlin P, Podoloff D, Hagemeister F, Younes A, Cabanillas F. Positron Emission Tomography Using Fluorodeoxyglucose but Not Gallium-67 Scintigraphy Is a Sensative Imaging Modality in the Staging of Mantle Cell Lymphoma. Blood 100:3041, 2002.
195. Younes A, Fayad LE, McLaughlin P, Goy A, Romaguera J, Rodriguez MA, Hagemeister F, Samaniego F, Pro B, Medeiros J, Ha C, Wilder R, Seifert A. Rituximab Plus ABVD Therapy for Newly Diagnosed Patients with Classical Hodgkin’s Disease. Blood 100:4774, 2002.
196. Younes A, Fayad L, Pro B, Romaguera J, Ha CS, Wilder R. Safety and Efficacy of Prophylactic Pegfilgrastim in Patients with Hodgkin Disease Receiving ABVD Chemotherapy. Blood 100:4179, 2002.
197. Fayad L, Romaguera J, Pro B, Younes A, Dang N, Samaniego F, Garcia P, Sarris A, Rodriguez MA, Hagemeister F, McLaughlin P, Goy A, Cabanillas F, P Rodriguez. Primary Mediastinal Large B-Cell lymphoma (PMLBL): Poor prognosis in patients with extranodal sites. Blood 98(11):Part I of II (#1419), 11/2001.
198. Fayad L, Estey E, Thomas D, O’Brien S, Keating M, Koller C, Pierce S, Talpaz S, Boyer K, Freireich E, Kantarjian H, Kurzrock R. Treatment of Hairy Cell Leukemia with Cladribine (2CDA): Long-term follow-up at M.D. Anderson Cancer Center. Blood 98(11) (#2659), 11/2001.

Grant & Contract Support

Title: Principal Investigator, Translational Research Inciatives (CTEP), approved to evaluate histone deacetylation in patients with DLBCL and MCL treated with HDAC inhibitor Depsipeptide
Funding Source: CTEP
Role: Principal Investigator
Duration: 11/2006 - 10/2009
 
Title: Phase II Depsipeptide for Recurren/refractory mantle cell lymphoma and DLBCL
Funding Source: n/a
Role: Principal Investigator
Duration: 2006 - 2010

Last updated: 8/29/2014